IL-17 and tumour necrosis factor α combination induces a HIF-1α-dependent invasive phenotype in synoviocytes

Ann Rheum Dis. 2012 Aug;71(8):1393-401. doi: 10.1136/annrheumdis-2011-200867. Epub 2012 Apr 24.

Abstract

Objectives: To examine the effect of interleukin-17 (IL-17) on rheumatoid arthritis (RA) synoviocyte migration and invasiveness.

Methods: IL-17A and tumour necrosis factor α (TNFα)-induced messenger RNA expression in RA synoviocytes was analysed using Affymetrix U133A microarrays. The capacity of IL-17 alone or in combination with TNFα to induce synoviocyte migration and invasion was tested using Boyden and transwell Matrigel invasion chambers. A functional DNA binding assay was used to evaluate the regulation of the key hypoxia-related gene hypoxia-inducible factor 1 (HIF-1α) expression and activation. The role of metalloproteinase 2 (MMP2) in IL-17-induced invasiveness was assessed using small interfering RNA. Hypoxia pathway gene expression was measured in the blood of RA patients and healthy volunteers using Affymetrix microarrays.

Results: Among the genes induced by IL-17A in RA synoviocytes, a molecular pattern of inflammation hypoxia-related genes, including CXC chemokine receptor 4 (CXCR4) and MMP2 was identified. Using immunofluorescence microscopy, the expression of CXCR4 was confirmed on synoviocytes. IL-17A and TNFα induced synoviocyte migration and invasion through a CXCR4-dependent mechanism with a synergistic effect. Their combination activated HIF-1α through the nuclear factor κB pathway. IL-17 enhanced invasion through MMP2 induction as demonstrated using siRNA. Finally, hypoxia genes were overexpressed in the blood of RA patients.

Conclusion: IL-17A, specifically when combined with TNFα may contribute to the progression of RA, notably through their effect on synoviocyte aggressiveness. Part of this effect results from activation of the CXCR4/stromal cell-derived factor 1 and hypoxia-mediated pathways.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arthritis, Rheumatoid / metabolism*
  • Arthritis, Rheumatoid / pathology
  • Cell Movement / drug effects
  • Cells, Cultured
  • DNA-Binding Proteins
  • Drug Combinations
  • Drug Synergism
  • Female
  • Gene Expression Profiling
  • Gene Expression Regulation / drug effects
  • Gene Silencing / drug effects
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit / genetics
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism*
  • Interleukin-17 / pharmacology*
  • Male
  • Matrix Metalloproteinase 2 / genetics
  • Matrix Metalloproteinase 2 / metabolism
  • Oligonucleotide Array Sequence Analysis
  • Phenotype
  • RNA, Messenger / metabolism
  • RNA, Small Interfering / pharmacology
  • Receptors, CXCR4 / metabolism
  • Recombinant Proteins
  • Synovial Membrane / drug effects*
  • Synovial Membrane / metabolism
  • Synovial Membrane / pathology
  • Tumor Necrosis Factor-alpha / pharmacology*

Substances

  • CXCR4 protein, human
  • DNA-Binding Proteins
  • Drug Combinations
  • HIF1A protein, human
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • IL17A protein, human
  • Interleukin-17
  • RNA, Messenger
  • RNA, Small Interfering
  • Receptors, CXCR4
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • MMP2 protein, human
  • Matrix Metalloproteinase 2